Skip to Content
Merck
  • Fascia tissue engineering with human adipose-derived stem cells in a murine model: Implications for pelvic floor reconstruction.

Fascia tissue engineering with human adipose-derived stem cells in a murine model: Implications for pelvic floor reconstruction.

Journal of the Formosan Medical Association = Taiwan yi zhi (2013-06-25)
Man-Jung Hung, Mei-Chin Wen, Ying-Ting Huang, Gin-Den Chen, Min-Min Chou, Vivian Cheng Yang
ABSTRACT

Mesh-augmented vaginal surgery for treatment of pelvic organ prolapse (POP) does not meet patients' needs. This study aims to test the hypothesis that fascia tissue engineering using adipose-derived stem cells (ADSCs) might be a potential therapeutic strategy for reconstructing the pelvic floor. Human ADSCs were isolated, differentiated, and characterized in vitro. Both ADSCs and fibroblastic-differentiated ADSCs were used to fabricate tissue-engineered fascia equivalents, which were then transplanted under the back skin of experimental nude mice. ADSCs prepared in our laboratory were characterized as a group of mesenchymal stem cells. In vitro fibroblastic differentiation of ADSCs showed significantly increased gene expression of cellular collagen type I and elastin (p < 0.05) concomitantly with morphological changes. By contrast, ADSCs cultured in control medium did not demonstrate these changes. Both of the engrafted fascia equivalents could be traced up to 12 weeks after transplantation in the subsequent animal study. Furthermore, the histological outcomes differed with a thin (111.0 ± 19.8 μm) lamellar connective tissue or a thick (414.3 ± 114.9 μm) adhesive fibrous tissue formation between the transplantation of ADSCs and fibroblastic-differentiated ADSCs, respectively. Nonetheless, the implantation of a scaffold without cell seeding (the control group) resulted in a thin (102.0 ± 17.1 μm) fibrotic band and tissue contracture. Our results suggest the ADSC-seeded implant is better than the implant alone in enhancing tissue regeneration after transplantation. ADSCs with or without fibroblastic differentiation might have a potential but different role in fascia tissue engineering to repair POP in the future.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glycolic acid, BioXtra, ≥98.0% (titration)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Streptomycin sulfate salt, powder
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Streptomycin sulfate salt, powder, BioReagent, suitable for cell culture
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Glycolic acid, ReagentPlus®, 99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Glycolic acid solution, high purity, 70 wt. % in H2O
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Glycolic acid solution, technical grade, 70 wt. % in H2O
SKU
Pack Size
Availability
Price
Quantity
Supelco
Glycolic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
SKU
Pack Size
Availability
Price
Quantity
Streptomycin sulfate, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Glycolic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Pack Size
Availability
Price
Quantity
Supelco
Streptomycin solution, ~1 mg/mL in 1 mM EDTA, analytical standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Streptomycin Ready Made Solution, 100 mg/mL in water
SKU
Pack Size
Availability
Price
Quantity